INTRODUCTION
Nearly three decades after the identification of HIV-1, considerable progress has been made in understanding the mechanisms by which HIV evades and profoundly damages the immune system, but a vaccine that reliably prevents or controls HIV remains elusive. Important insights into correlates of protective immunity can be gained from studying SIV in animal models and human subjects infected with HIV-1 who do not develop immunodeficiency. One such model that has not been adequately investigated is infection with HIV-2. HIV-1 and HIV-2 share 30-60% sequence identity and show many similarities in their cytopathic potential and replication kinetics in vitro in that a substantial proportion of infected people (approx. 37% in our cohort) maintain an undetectable plasma viral load (VL) for over a decade with no signs of immunodeficiency 3 . Unlike the rare phenomenon of "elite control" in HIV-1 infection, this phenotype is both clinically stable and occurs more commonly than disease progression. Nevertheless, those with HIV-2 who develop disease (15-20%) do so in a manner 4 and time-frame 5 that cannot be distinguished clinically from HIV-1 infection. Identifying the key differences between these two groups at either end of the HIV-2 clinical spectrum should provide insights into the mechanisms by which humans can control infection with a potentially pathogenic retrovirus. Furthermore, recent data has suggested that preceding HIV-2 infection can limit the rate of disease progression and HIV-1 viral evolution following HIV-1 super-infection
As cross-reactive HIV-2 Gag-specific cytotoxic T-lymphocyte (CTL) responses 7 , 8 are a possible explanation for these observations, characterization of CD8+ Tcells in HIV-2-infected subjects could aid our understanding of what would be required of a vaccine that could successfully contain HIV-1 via induction of T-cell responses.
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We have previously shown that HIV-2-infected subjects with high CD4+ counts are more likely to preserve polyfunctional virus-specific T-cell responses than their HIV-1-infected counterparts 9, 10 , but whether these responses distinguish HIV-2 controllers from viraemic progressors is not known.
When the T-cell response towards the HIV-2 proteome was compared between these two groups, viral control was strongly associated with high magnitude HIV-2 Gag-specific responses 11 .
However, this study was performed using ELISpot assays that did not distinguish between CD4+
and CD8+ responses and further detailed phenotypic and functional characterization of this potentially protective response is lacking. Here we present data from a study of HIV-2 Gag-specific T-cell responses from subjects selected to represent both controllers and viraemic subjects, in order to identify the cellular immune correlates of HIV-2 viral control. Our study arguably represents the most comprehensive analysis of HIV-2-specific T-cells to date, including detailed ex vivo phenotypic analysis of CD8+ T-cells targeting several immunodominant epitopes and direct comparison of both cytokine-mediated and cytotoxic functional capacity in HIV-2 controllers and viraemic subjects.
MATERIALS AND METHODS

Study subjects
Antiretroviral therapy (ART) naïve HIV-2 mono-infected subjects from the Caió community cohort in rural Guinea-Bissau were recruited following informed consent. This cohort was established in 1989 and has followed HIV-2 infected individuals identified via community serosurveys for over two decades CD4+ T-cell subset analysis was performed using fresh whole blood staining with two-colour immunofluorescence reagents (anti-CD45/anti-CD4) and a CyFlow-SL flow cytometer (Partec). Peripheral blood mononuclear cells (PBMCs) were cryopreserved. Confirmation of HIV-2 status was undertaken using a diagnostic algorithm involving both serological and molecular
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From each measured marker (CD107a, IFN-γ, TNF-α, IL-2 and perforin), which determined the frequency of each response pattern based on all possible combinations. Responses detected in the negative (anti-CD28/anti-CD49d) control were subtracted from responses observed in stimulated samples for each response individually prior to further analysis. In cases where the stimulated sample value is smaller than that of the anti-CD28/anti-CD49d control, negative values arise. These were set to zero. To avoid systematic bias with this approach, a threshold was set below which all positive values were also zeroed on the assumption that the distribution of background values is symmetric around zero 16 . This threshold (0.009 for the CD8+ and 0.01 for the CD4+ dataset) was chosen based on the distribution of negative values for each dataset of twice the 90th centile.
Tetramer staining and polychromatic flow cytometry
Assays were performed at the Weatherall Institute of Molecular Medicine (Oxford) and cells analyzed with an LSRII flow cytometer (BD). Cryopreserved PBMCs were thawed as described above. 1 x 10 6 live PBMCs were stained with Aqua for 30min at 4°C followed by 1µg of tetramer-PE for 15min at 37°C. Surface staining with CD3-Qdot655, CD4-Qdot605, CD8-Qdot705, CD14-V500, CD19-V500, CD27-efluor780, CD45RO-TexasRedPE, CD57-Qdot565 and PD-1-PECy7, as well as 2B4-PECy5.5 and CD160-efluor647 in panel-1, and CD38-APC and HLA-DRAlexafluor700 in panel-2 were performed. Following fixing and permeabilization, intracellular staining with Perforin-FITC, Granzyme B-Alexafluor700 and T-bet-Brilliant Violet in panel-1 and Ki67-Alexafluor488 and Bcl-2-V450 in panel-2 were done. FMO samples were included to aid gating during subsequent flow cytometric analysis.
Electronic compensation was performed as described above. Between 500,000 and 1,000,000 events were acquired for each sample. FSC area and FSC height were used to exclude cell aggregates, followed by removal of CD14+, CD19+, dead cells and gating on CD3+ cells. FSC and
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From polyfunctional CD4+ T-cells was similar between the two groups, the proportion of the total CD4+ response expressing ≥ 3 functions was significantly higher in HIV-2 controllers (Fig 1c and d) . A greater proportion of the Gag-specific CD8+ response consisted of IFN-γ and TNF-α producing cells in controllers (Fig 2a) . The frequency of polyfunctional CD8+ T cells was significantly higher in controllers (Fig 2b) and polyfunctionality correlated inversely with plasma VL (Fig 2c) . In contrast, the proportion of the CD8+ T-cell response made up of mono-functional cells increased with higher VL (Fig 2d) . No significant association was observed between CD4+ count and the CD8+ IFN-γ response or polyfunctionality (Fig S3) . Using median fluorescence intensity (MFI) of each parameter as a proxy for the amount of cytokine produced per cell, we also observed, as previously described
10
, that polyfunctional Gag-specific CD8+ T-cells secreted more IFN-γ ( Fig S4) and TNF-α, but not CD107a or IL-2 (data not shown) than their 'less functional' counterparts.
HIV-2 Env-specific responses (measured in 25 HIV-2 controllers and 14 viraemic subjects) were almost exclusively from CD8+ T-cells (data not shown). No significant difference in the magnitude of the Env-specific CD8+ IFN-γ response was observed between the two groups ( Fig S5) . Gagspecific CD8+ responses were more polyfunctional than Env-specific responses, although this difference was primarily found in HIV-2 controllers (Fig S6) .
The HIV-2 Gag-specific CD8+ T-cell response is highly focused and often absent in viraemic individuals
Peptide-MHC class I tetramers specific for four immunodominant HIV-2 Gag epitopes in this cohort 11 were used to determine the phenotype of HIV-2-specific CD8+ T-cells (HLA B53, B58, B35 and B14-restricted). CTLs targeting two of these epitopes (B35 and B58-restricted) are also known to recognise the equivalent regions in HIV-1 were five CMV-specific and eight EBV-specific tetramer-staining populations. Frequencies of all tetramer-staining populations are detailed in Table S2 .
A greater proportion of HIV-2 controllers compared to viraemic subjects had tetramer-staining populations (84% vs. 42%, p = 0.02, Fig 3b) . This is an important observation but prevented a meaningful comparison of HIV-2 specific CD8+ T-cell phenotype between the two groups and therefore all HIV-2 populations were analysed together (25 tetramer-staining populations from 21
HIV-2-infected individuals: 16 controllers, five viraemic). We observed a strong correlation (r = 0.71) between the magnitude of the CD8+ IFN-γ response to the total Gag pool (by ICS) and the % of tetramer-staining T-cells in each subject (Fig 3c) , suggesting that the bulk of the Gag-specific response in these subjects is accounted for by CD8+ T-cells targeting one or more of these epitopes.
We then reanalyzed previously reported IFN-γ ELISpot data from the same cohort, generated using a 3D-peptide matrix 11 . The total Gag pool-specific magnitude was significantly greater in individuals who responded to ≥ 1 of these four HIV-2 Gag epitopes (40/64, 62.5%) than to those who did not (Fig 3d) : median (IQR) 1103 (524 -2081) SFU/ml vs. 195 (0 -481) SFU/ml, thus confirming the remarkable immunodominance of these epitopes. Furthermore, of the individuals who displayed B53, B58, B35 or B14-restricted responses, 32/40 (80%) responded to only one of these peptides. This represents an incredibly restricted breadth in the HIV-2-specific Gag response
shown to be associated with viraemic control.
Control of HIV-2 viraemia is not associated with CD8+ T-cells with high cytotoxic potential
HIV-1 control is associated with the capacity of HIV-1-specific CD8+ T-cells to express perforin on antigen stimulation, as well as enrichment of other cytolytic markers 19, 20 . We explored whether similar qualities are required for HIV-2 control. Although perforin co-expression (with one or more of IFN-γ, TNF-α, IL-2 and CD107a 20 ) was readily identifiable following both SEB and Gag stimulation, this did not differentiate HIV-2 controllers from viraemic subjects (Fig 4a and 4b) . We also assessed the degree of ex vivo perforin, granzyme B and T-bet expression in virus-specific CD8+ T-cells. When compared to bulk CD8+ T-cells, HIV-2-specific T-cells showed modest increases in granzyme B, similar expression of T-bet and lower levels of perforin (Fig 4c) .
Expression levels on viraemic donor cells did not cluster together. CMV-specific CD8+ T-cells displayed significantly higher granzyme B and T-bet expression than HIV-2 and EBV-specific Tcells (Fig 4d) . Analysis of T-bet MFI revealed a similar picture (data not shown).
HIV-2-specific CD8+ T-cells display an earlier differentiated phenotype
Previous studies have shown significant heterogeneity in the phenotype of CD8+ T-cells specific for different chronic viral infections 21, 22 . HIV-2-specific CD8+ T-cells displayed greater CD27
expression than CMV-specific CD8+ T-cells (Fig 5a and 5c ), representing T-cells at an earlier stage of differentiation. No clear pattern was observed in controllers vs. viraemic donor cells (Fig 5a) .
While CMV-specific T-cells tended to display a 'terminal effector' phenotype of CD27-/CD45RO-, HIV-2-specific and EBV-specific T-cells were more frequently CD27+/CD45RO+ (Fig 4b and 4c ).
No significant difference was seen in antigen-specific CD8+ T-cell senescence based on expression of CD57 (data not shown).
HIV-2-specific CD8+ T-cells display high levels of PD-1, 2B4 and CD160 expression
Recent data have defined a relationship between co-expression of multiple inhibitory receptors (PD-1/2B4/CD160) on HIV-1-specific CD8+ T-cells and higher viraemia, suggesting these represent a 'hyper-exhausted' cellular phenotype
23
. However, HIV-2-specific CD8+ T-cell populations (largely from individuals with undetectable VLs and polyfunctional Gag responses) have surprisingly higher levels of PD-1/2B4/CD160 co-expression than bulk CD8+ populations (Fig 6a) . Furthermore, a significant direct correlation was observed between co-expression of PD-1/2B4/CD160 and the For personal use only. on October 28, 2017. by guest www.bloodjournal.org From magnitude of the Gag-specific IFN-γ response (r = 0.48, p = 0.027, Fig S7) . CMV-specific CD8+ Tcells displayed significantly lower co-expression of inhibitory receptors (Fig 6b and 6c) . We therefore hypothesized that PD-1/2B4/CD160 expression may be related to cellular differentiation status. Accordingly, a strong correlation was observed between both PD-1 expression, as well as PD1/2B4/CD160 co-expression, with CD27+CD45RO+CD8+ T-cells (Fig S8) (r = 0.69, p = 0.0002 and r = 0.75, p < 0.0001 respectively).
HIV-2-specific CD8+ T-cells display low levels of activation and proliferation ex vivo. proposed that an increased susceptibility to apoptosis in CD8+ T-cells expressing high levels of CD38 may result in a failure to control HIV-1 replication 27 . Accordingly, a strong inverse correlation was seen between CD38 expression and presence of Bcl-2, an anti-apoptotic marker, on HIV-2-specific CD8+ T-cells (r s = -0.618, p = 0.001, Fig S9d) . . Highly differentiated CD8+ T-cell subsets described in some HIV-1 controllers also have the ability to rapidly upregulate cytotoxic granule contents on stimulation, and express higher levels of the transcription factor T-bet 19, 20, 42 . Surprisingly, we find that HIV-2-specific CD8+ T-cells (largely from individuals with low/undetectable VLs) are characterized by low levels of pre-loaded cytotoxic molecules, and that rapid upregulation of perforin after Gag stimulation does not distinguish HIV-2 controllers from viraemic subjects. In keeping with this observation, HIV-2-specific CD8+ T-cells are of an earlier differentiated phenotype.
cell supernatant alone from HIV-2 specific CD8+ T-cell clone cultures are able to partially suppress HIV-2 replication in CD4+ T-cell lines (AL, unpublished data). Further functional studies evaluating both the cytolytic activity and suppressive capacity of soluble factors secreted from primary HIV-2 specific CD8+ T-cells are required.
Studies exploring the relationship between antigen burden and cellular differentiation offer a potential explanation for the earlier differentiation phenotype of HIV-2 specific CD8+ T-cells 43, 44 .
Using both ex vivo antigen-specific CD8+ T-cell analysis and a model of in vitro T-cell priming, our previous study suggests that higher viral burden drives T-cell differentiation in HIV infection through greater immune activation 43 . Consistent with these data, HIV-1 sero-converters with higher VL set points have greater frequencies of differentiated effector memory HIV-1-specific CD8+ Tcells and higher activation levels . Although studies of acute HIV-2 infection are lacking, it is likely that the VL set point of HIV-2 controllers is low, which may explain the persistent CD27 expression observed in chronic infection. The low activation levels observed in HIV-2-specific CD8+ T-cells in our current study are also in keeping with this hypothesis. Furthermore, we find high co-expression of PD-1/2B4/CD160 on HIV-2-specific CD8+ T-cells. Although robust data exist to suggest an inhibitory role for these markers in HIV-1 disease and does not affect the ability of CD8+ T-cells to secrete cytokines in healthy adults 46 .
How could HIV-2-specific CD8+ responses with a limited specificity control HIV-2 for decades?
Highly functional but narrow responses remain beneficial only if viral escape does not occur, resulting in uncontrolled viral replication in the absence of responses to other regions. Despite the fitness costs associated with mutation, escape from Gag-specific CD8+ T-cell responses is frequently seen in HIV-1 infection. Selection analyses comparing HIV-1 and HIV-2 env 47 and gag (TdS, unpublished) reveal that HIV-2 is under greater negative selective pressure than HIV-1, suggesting far greater functional and structural constraints are imposed on HIV-2. CD8+ T-cell epitope escape in HIV-2 has not been described and viral sequences from individuals with potent Gag-specific responses (and therefore selective pressure) show a high degree of conservation in respective epitopes 48 . Thus low VL set points and a functionally constrained virus may allow the persistence of initial CD8+ T-cell responses targeting conserved epitopes, which can contribute to viral control for years.
Our study is relatively limited by being based in a single cohort, although the long follow up in a genetically homogeneous population infected with the same HIV-2 group (A) is also a major strength that is difficult to reproduce in HIV-1 controller cohorts. It would be important to corroborate our findings in subjects with different HLA allele distributions. A key limitation worth discussing is the difficulty in determining whether the potent responses observed represent the cause of HIV-2 viral control, or if they simply a reflect an undamaged immune system due to limited viral replication secondary to other factors. We fail to show an association between CD4+
counts (a marker of immunodeficiency) and the HIV-2 Gag specific CD8+ T-cell response, which may argue for a causative role. Alternative strategies to explore this problem may be helpful.
Studying the evolution of HIV-2-specific CD8+ responses and VLs in HIV-2 controllers who acquire HIV-1 superinfection (i.e. suffer further immunological damage) may provide some insight.
Such studies would also be key in determining whether T-cell responses, such as those described in this study, are responsible for attenuating the course of acute HIV-1 in HIV-1/2 dually infected subjects 6 via cross-recognition of HIV-1 epitopes. The strongest evidence for a causative role could be established by achieving control of HIV-2 in viraemic individuals via immuno-therapeutic strategies designed to induce CD8+ T-cell responses. Such measures could provide proof-ofconcept for future induction of HIV-1 immune-mediated control and allow valuable lessons to be
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From learned. It may also provide a therapeutic option for clinical care of HIV-2-infected subjects, who are often disadvantaged by sub-optimal ART regimes, compounded by the lack of reliable drug procurement in resource-limited settings.
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